GlassScriptPhysician profile
Raul Mendoza
NPI 1457357667
$1,918.39
in general payments reported to CMS, 2019-2025
16 companies · $346 in 2025
The $346 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $101 · 2021: $45.77 · 2022: $139 · 2023: $211 · 2024: $590 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $448.84 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $311.33 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $213.25 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $211.91 | 2019-2022 | |
| Galvanize Therapeutics, INC | $137.15 | 2024 | Aliya System |
| Contego Medical, INC | $116.94 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $108.29 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $104.91 | 2020-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $93.52 | 2019-2024 | Lokelma, Farxiga |
| Pfizer INC. | $57.38 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.14 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.57 | 2019 | |
| Novo Nordisk INC | $19.32 | 2024 | Wegovy |
| Laborie Medical Technologies Corp. | $15.71 | 2024 | Kiwi Procup |
| Amarin Pharma, INC. | $14.90 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Mendoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.